维普中文期刊产品整合服务
61篇 您的检索式:作者名="Helen M C"
    题名 作者 年代 出处 被引量
1Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells显示文摘Arnold Isabelle C Dehzad Nina Reuter Sebastian Martin Helen Becher Burkhard Taube Christian Müller Anne 2011Journal of Clinical Investigation2011,,8:4
2Investigation of hydration and pozzolanic reaction in reactive powder concrete (RPC) using 29Si NMR显示文摘Helene Z Marcel C Vincent M 1996Cement and Concrete Research1996,26,1:1
3Analysis of nitrosamines in cosmetics显示文摘KANE I K-ETH G M HELENE C 1990J Soc Cosmet Chem1990,41,:1
4Codon usage and gene function are related in sequences of Arabidopsis thaliana 显示文摘Helene C Fr6d6rique L M ichel C Alain H 1998Gene1998,209,12:1
5Functional coupling of 3-adrenoceptors and large conductance calcium-activated potassium channels in human uterine myocytes显示文摘Helen C Doheny Caoimhe M 2005J Clin Endocrinol Metab2005,90,10:1
6Flaw tolerance and crack resistance properties of alumina-aluminium titanate composites with tailored microstructure显示文摘Nitin P P Stephen J B Helen M C 1993Journal of the American Ceramic Society1993,76,9:1
7Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase Ⅱ randomised placebo-controlled double-blind multicentre trial显示文摘Rationale Haematoma growth is common early after intracerebral haemorrhage(ICH),and is a key determinant of outcome.Tranexamic acid,a widely available antifibrinolytic agent with an excellent safety profile,may reduce haematoma growth.Methods and design Stopping intracerebral haemorrhage with tranexamic acid for hyperacute onset presentation including mobile stroke units(STOP-MSU)is a phase Ⅱ double-blind,randomised,placebo-controlled,multicentre,international investigator-led clinical trial,conducted within the estimand statistical framework.Hypothesis In patients with spontaneous ICH,treatment with tranexamic acid within 2 hours of onset will reduce haematoma expansion compared with placebo.Sample size estimates A sample size of 180 patients(90 in each arm)would be required to detect an absolute difference in the primary outcome of 20%(placebo 39%vs treatment 19%)under a two-tailed significance level of 0.05.An adaptive sample size re-estimation based on the outcomes of 144 patients will allow a possible increase to a prespecified maximum of 326 patients.Intervention Participants will receive 1 g intravenous tranexamic acid over 10 min,followed by 1 g intravenous tranexamic acid over 8 hours;or matching placebo.Primary efficacy measure The primary efficacy measure is the proportion of patients with haematoma growth by 24±6 hours,defined as either≥33%relative increase or≥6 mL absolute increase in haematoma volume between baseline and follow-up CT scan.Discussion We describe the rationale and protocol of STOP-MSU,a phase Ⅱ trial of tranexamic acid in patients with ICH within 2 hours from onset,based in participating mobile stroke units and emergency departments.Nawaf Yassi Henry Zhao Leonid Churilov Bruce C V Campbell Teddy Wu Henry Ma Andrew Cheung Timothy Kleinig Helen Brown Philip Choi Jiann-Shing Jeng Annemarei Ranta Hao-Kuang Wang Geoffrey C Cloud Rohan Grimley Darshan Shah Neil Spratt Der-Yang Cho Karim Mahawish Lauren Sanders John Worthington Ben Clissold Atte Meretoja Vignan Yogendrakumar Mai Duy Ton Duc Phuc Dang Nguyen Thai My Phuong Huy-Thang Nguyen Chung Y Hsu Gagan Sharma Peter J Mitchell Bernard Yan Mark W Parsons Christopher Levi Geoffrey A Donnan Stephen M Davis 2022Stroke & Vascular Neurology2022,7,2:1
8The prevalence and management of asthma in primary-aged schoolchildren in the south of England显示文摘DONNA M C JENNY M W HELEN C 2002Health Educ Res2002,97,2:1
9Breast feeding and mental and motor development at 12 months in a low-income population in northeast Brazil显示文摘Helenal E S De Carvalhol L M Becharal C S 2007Paediatric & Perinatal Epidemiology2007,21,2:1
10Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth显示文摘 Jean M Mary Z 2001The Journal of Clinical Endocrinology & Metabolism2001,86,:1
11A formal model for consensus and negotiation in environmental management显示文摘HELEN M R MAR K C LISA M N 2006Journal of Environmental Management2006,80,2:1
12The Ability of Dissolved Organic Matter (DOM) to Influence Benzopyrene Bioavailability Increases with DOM Biodegradation显示文摘GOURLAY C HELENE M VUILLEMIN T 2005Ecotoxicology and Environmental Safety2005,61,:1
13Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia显示文摘BACKGROUND Sleep disturbance is a core feature of post-traumatic stress disorder(PTSD).Given the relationship between sleep disturbance and PTSD,there has been a relative paucity of studies examining the potential therapeutic impact of using pharmacotherapy to target sleep disturbance in patients with PTSD.Eszopiclone(ESZ)is a non-benzodiazepine y-aminobutyric acid-A receptor agonist indicated for the treatment of sleep and may affect sleep in patients with PTSD.AIM To evaluate the efficacy of ESZ vs placebo(PBO)for patients with PTSD and insomnia.METHODS The study was a 12-wk,double blind,randomized controlled trial with 3 mg of ESZ(n=13)or PBO(n=12).RESULTS Patients in both arms experienced significant improvement in PTSD symptoms as assessed by the Clinician-Administered PTSD Scale for DSM-IV(CAPS):ESZ(t11=-3.12,P=0.005)and PBO(t11=-3.5,P=0.002)and by self-report with the Short PTSD Rating Interview(ESZ t11=-3.38,P=0.003 and PBO t11=-4.48,P=0.0005).There were no significant differences between treatments on the CAPS(t22=-0.13,P=0.70)or the Short PTSD Rating Interview(t22=-0.58,P=0.56).Similarly,both treated groups improved on sleep measures as assessed by the Pittsburgh Sleep Quality Index with PTSD Addendum(PSQI)and on total sleep time(TST)and sleep latency assessed by actigraphy with no significant differences between groups(PSQI t22=-0.24,P=0.81;total sleep time t10=0.13,P=0.90 and sleep latency t10=0.68,P=0.50).There was a significant correlation between improvement in sleep and overall improvement in PTSD as measured by change scores on the PSQI and CAPS,r(8)=0.79,P=0.01 for ESZ treated subjects,but not for those treated with PBO r(9)=0.16,P=0.69.Adverse events of ESZ were consistent with the known profile of the medication including dysgeusia(30%,mild),sedation(20%,mild)and headache(20%,moderate to severe).CONCLUSION Results do not support the hypothesis of a specific positive effect of ESZ compared to PBO for measures of PTSD and associated sleep disturbance.Sheila M Dowd Alyson K Zalta Helen J Burgess Elizabeth C Adkins Zerbrina Valdespino-Hayden Mark H Pollack 2020World Journal of Psychiatry2020,10,3:1
14Change in maternal concerns during the six weeks postpartum period: a study of primiparous mothers in Dar Es Salaam, Tanzania 显示文摘Helen I L Kyllike C Siriel M 2001J Midwifery & Women''s Health2001,46,4:1
15Personal authentication using hand images 显示文摘A JAY K DAVID C M W HELEN C SH 2006Pattern Recognition Letter2006,,27:1
16Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial显示文摘Perkins Bruce A Cherney David ZI Partridge Helen Soleymanlou Nima Tschirhart Holly Zinman Bernard Fagan Nora M Kaspers Stefan Woerle Hans-Juergen Broedl Uli C Johansen Odd-Erik 2014Diabetes Care2014,,5:1
17Cord blood leptin and insulin-like growth factor levels are independent predictors of fetal growth显示文摘Helen C Jean M Mary Z 2001J Clin Endocrinol Metab2001,86,:1
18Biopotential mouse embryonic liver stem cell lines contribute to liver regeneration and differentiation as bile ducts and hepatocyte显示文摘Helene Strick-Marchand Serban M Pieere C 2004The National Academy of Sciences of the USA2004,10,22:1
19Functional coupling of β3-adrenoceptors and large conductance calcium-activated potassium channels in human uterine myocytes显示文摘Helen C Doheny Caoimhe M 2005The Journal of Clinical Endocrinology & Metabolism2005,90,10:1
20Cerebrovascular Disease and Late-Life Depression显示文摘Helen C Daniel F Alan M 2005Am J Geriatr Psychiatry2005,13,2:1
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费